Biogena Group Invest AG (WBO:BIO) EBIT: €0.30 Mil (TTM As of Jan. 2026)


WBO:BIO Biogena Group Invest AG WBO:BIO
66 GF Score
Price €4.20
GF Value €3.45
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biogena Group Invest AG EBIT?

Biogena Group Invest AG WBO:BIO -5.41% 66 EBIT is €0.30 Mil as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 66/100 and a GF Value™ of €3.45 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Biogena Group Invest AG's earnings before interest and taxes (EBIT) for the six months ended in Jan. 2026 was €0.30 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2026 was €0.30 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biogena Group Invest AG's annualized ROC % for the quarter that ended in Jan. 2026 was 2.02%. Biogena Group Invest AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biogena Group Invest AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was 1.77%.

Biogena Group Invest AG  (WBO:BIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biogena Group Invest AG's annualized ROC % for the quarter that ended in Jan. 2026 is calculated as:

ROC % (Q: Jan. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2025 ) + Invested Capital (Q: Jan. 2026 ))/ count )
=0.179 * ( 1 - 1.35% )/( (8.707 + 8.789)/ 2 )
=0.1765835/8.748
=2.02 %

where

Invested Capital(Q: Jan. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.941 - 0.222 - ( 0.012 - max(0, 0.226 - 1.424+0.012))
=8.707

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.86 - 0.047 - ( 0.024 - max(0, 0.051 - 1.342+0.024))
=8.789

Note: The Operating Income data used here is one times the annual (Jan. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Biogena Group Invest AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2025  Q: Jan. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.297/( ( (0 + max(-0.226, 0)) + (0 + max(-0.051, 0)) )/ 2 )
=0.297/( ( 0 + 0 )/ 2 )
=0.297/0
= %

where Working Capital is:

Working Capital(Q: Jan. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.222 + 0 + 0.004)
=-0.226

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.047 + 0 + 0.004)
=-0.051

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Jan. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biogena Group Invest AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jan. 2026 )
=0.297/16.734
=1.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogena Group Invest AG EBIT Related Terms

Biogena Group Invest AG EBIT Historical Data

* Premium members only.

The historical data trend for Biogena Group Invest AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogena Group Invest AG EBIT Chart

Biogena Group Invest AG Annual Data
Trend Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
EBIT
Get a 7-Day Free Trial 0.82 0.30 0.18 0.20 0.30

Biogena Group Invest AG Semi-Annual Data
Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
EBIT Get a 7-Day Free Trial 0.82 0.30 0.18 0.20 0.30

WBO:BIO vs KHC, GIS, HRL: EBIT Comparison

For the Packaged Foods subindustry, Biogena Group Invest AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogena Group Invest AG EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biogena Group Invest AG's EV-to-EBIT falls into.


WBO:BIO
66GF Score
Biogena Group Invest AG WBO:BIO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogena Group Invest AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Jan. 2026 was €0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €0.30 Mil mean?
Biogena Group Invest AG (WBO:BIO) has a EBIT of €0.30 Mil as of Jan. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biogena Group Invest AG.
Is Biogena Group Invest AG's EBIT too high?
Biogena Group Invest AG's current EBIT is €0.30 Mil. Overall, Biogena Group Invest AG has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's EBIT compare to KHC and GIS?
Biogena Group Invest AG's EBIT of €0.30 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biogena Group Invest AG. Biogena Group Invest AG's current EBIT is €0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.45, compared to a current price of €4.20 — trading 21.7% above its estimated fair value. The current EBIT is €0.30 Mil. Biogena Group Invest AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current EBIT is €0.30 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued. The current stock price of €4.20 is trading 21.7% above its estimated GF Value™ of €3.45. GuruFocus considers Biogena Group Invest AG to be Modestly Overvalued.

Key valuation signals for WBO:BIO:

  • EBIT: €0.30 Mil
  • GF Value™: €3.45 vs. price of €4.20 (21.7% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogena Group Invest AG Business Description

Address Strubergasse 24, Salzburg, AUT, 5020
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
66GF Score

Get the complete analysis for WBO:BIO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.20
Price
€3.45
GF Value